Skip to main content
SpringerLink
Log in

Methods for Pathological Classification of Alzheimer’s Disease

  • Protocol
  • First Online:
Biomarkers for Preclinical Alzheimer’s Disease

Part of the book series: Neuromethods ((NM,volume 137))

  • 1068 Accesses

Abstract

The hallmark protein aggregates required for a neuropathological diagnosis of Alzheimer’s disease are intracellular neurofibrillary tangles and neuropil threads consisting of hyperphosphorylated tau, extracellular parenchymal amyloid β plaques, and neuritic plaques. In this chapter, we describe the neuropathological criteria for the neuropathological diagnosis of Alzheimer’s disease, as well as the fixation, processing, and histology protocols required for the assessment of post-mortem human brains.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Halliday GM, Double KL, Macdonald V et al (2003) Identifying severely atrophic cortical subregions in Alzheimer's disease. Neurobiol Aging 24(6):797–806

    Article  CAS  PubMed  Google Scholar 

  2. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8(9):663–672. https://doi.org/10.1038/nrn2194

    Article  CAS  PubMed  Google Scholar 

  3. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259

    Article  CAS  PubMed  Google Scholar 

  4. Braak H, Alafuzoff I, Arzberger T et al (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389–404. https://doi.org/10.1007/s00401-006-0127-z

    Article  PubMed  PubMed Central  Google Scholar 

  5. Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 121(2):171–181. https://doi.org/10.1007/s00401-010-0789-4

    Article  PubMed  Google Scholar 

  6. Braak H, Thal DR, Ghebremedhin E et al (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70(11):960–969. https://doi.org/10.1097/NEN.0b013e318232a379

    Article  CAS  PubMed  Google Scholar 

  7. Attems J, Thomas A, Jellinger K (2012) Correlations between cortical and subcortical tau pathology. Neuropathol Appl Neurobiol 38(6):582–590. https://doi.org/10.1111/j.1365-2990.2011.01244.x

    Article  CAS  PubMed  Google Scholar 

  8. Giannakopoulos P, Herrmann FR, Bussiere T et al (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60(9):1495–1500

    Article  CAS  PubMed  Google Scholar 

  9. Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3):885–890

    Article  CAS  PubMed  Google Scholar 

  10. Naslund J, Haroutunian V, Mohs R et al (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283(12):1571–1577

    Article  CAS  PubMed  Google Scholar 

  11. Younkin SG (1995) Evidence that a beta 42 is the real culprit in Alzheimer's disease. Ann Neurol 37(3):287–288. https://doi.org/10.1002/ana.410370303

    Article  CAS  PubMed  Google Scholar 

  12. Thal DR, Rub U, Orantes M et al (2002) Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791–1800

    Article  PubMed  Google Scholar 

  13. Guntert A, Dobeli H, Bohrmann B (2006) High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143(2):461–475. https://doi.org/10.1016/j.neuroscience.2006.08.027

    Article  CAS  PubMed  Google Scholar 

  14. Mirra SS, Heyman A, McKeel D et al (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41(4):479–486

    Article  CAS  PubMed  Google Scholar 

  15. Attems J, Jellinger K, Thal DR et al (2011) Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 37(1):75–93. https://doi.org/10.1111/j.1365-2990.2010.01137.x

    Article  CAS  PubMed  Google Scholar 

  16. Vinters HV (1987) Cerebral amyloid angiopathy. A critical review. Stroke 18(2):311–324

    Article  CAS  PubMed  Google Scholar 

  17. Attems J (2005) Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 110(4):345–359. https://doi.org/10.1007/s00401-005-1074-9

    Article  CAS  PubMed  Google Scholar 

  18. Attems J, Jellinger KA (2004) Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology--a pilot study. Acta Neuropathol 107(2):83–90. https://doi.org/10.1007/s00401-003-0796-9

    Article  PubMed  Google Scholar 

  19. Thal DR, Ghebremedhin E, Orantes M et al (2003) Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 62(12):1287–1301

    Article  PubMed  Google Scholar 

  20. Pfeifer LA, White LR, Ross GW et al (2002) Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 58(11):1629–1634

    Article  CAS  PubMed  Google Scholar 

  21. Vinters HV, Gilbert JJ (1983) Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 14(6):924–928

    Article  CAS  PubMed  Google Scholar 

  22. Tomonaga M (1981) Cerebral amyloid angiopathy in the elderly. J Am Geriatr Soc 29(4):151–157

    Article  CAS  PubMed  Google Scholar 

  23. Thal DR, Ghebremedhin E, Rub U et al (2002) Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61(3):282–293

    Article  PubMed  Google Scholar 

  24. Love S, Chalmers K, Ince P et al (2014) Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis 3(1):19–32

    PubMed  PubMed Central  Google Scholar 

  25. Montine T, Phelps C, Beach T et al (2012) National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathologica 123:1–11

    Article  CAS  PubMed  Google Scholar 

  26. Hyman BT, Phelps CH, Beach TG et al (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association 8(1):1–13. https://doi.org/10.1016/j.jalz.2011.10.007

    Article  Google Scholar 

  27. Alafuzoff I, Arzberger T, Al-Sarraj S et al (2008) Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe consortium. Brain pathol (Zurich, Switzerland) 18(4):484–496. https://doi.org/10.1111/j.1750-3639.2008.00147.x

    PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank Lynne Ramsay and Ros Hall for their technical expertise and assistance in writing this chapter and Dr. Christopher Morris and the Newcastle Brain Tissue Resource for providing the photographic images.

Author information

Authors and Affiliations

  1. Institute for Neuroscience, Newcastle University, Newcastle upon Tyne, UK

    Johannes Attems, Kirsty E. McAleese & Lauren Walker

Authors
  1. Johannes Attems
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kirsty E. McAleese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lauren Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johannes Attems .

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany

    Robert Perneczky

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Attems, J., McAleese, K.E., Walker, L. (2018). Methods for Pathological Classification of Alzheimer’s Disease. In: Perneczky, R. (eds) Biomarkers for Preclinical Alzheimer’s Disease. Neuromethods, vol 137. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7674-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7674-4_5

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7673-7

  • Online ISBN: 978-1-4939-7674-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation